Jun Ishihara

Dr. Ishihara received a BS in Applied Chemistry from Waseda University, and a PhD in Medical Genome Science from the University of Tokyo. He first joined the Hubbell Laboratory in EPFL, Switzerland as a post-doctoral fellow, and has moved with the lab to UChicago. His reseach interest are drug delivery, cancer immunotherapy, regenerative medicine.

Lab Information

Hubbell Lab, University of Chicago

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Drug discovery 1 Cell immunology 1

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (4)
Collagen-binding IL-12 may potentiate CPI immunotherapy fo ...
Post

Reply

Follower

Checkpoint-inhibitor (CPI) immunotherapy has achieved remarkable clinical success, yet its efficacy in ‘immunologically cold’ tumours has been modest. Interleukin-12 (IL-12) is a powerful cytokine that activates the innate and adaptive arms of the immune system; however, the ...Learn More

  1. Ishihara J, Ishihara A, Sasaki K, et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019;11(487)


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Co-build a Global Biological Community
Cloud Scientists
View all
Ezcoupon Reward Program

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud